Related Experiment Video
Updated: Jul 2, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus
Eamonn S Molloy1, Leonard H Calabrese
1Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio 44195, USA. molloye@ccf.org
Abstract:
Progressive multifocal leukoencephalopathy (PML) is a rare, frequently fatal, infectious complication occurring in immunocompromised patients. PML has been well-reported in patients with chronic inflammatory rheumatic diseases taking immunosuppressive drugs. Awareness of the occurrence of PML in patients with rheumatic diseases has recently been highlighted by the occurrence of several cases of PML following administration of natalizumab and rituximab, biologic agents which have been used for the treatment of rheumatic diseases. Nearly two thirds of cases of PML in patients with rheumatic diseases reported in the medical literature occurred in patients with systemic lupus erythematosus (SLE). Over 40% of PML cases in SLE occurred in patients who had had minimal iatrogenic immunosuppression, suggesting that SLE itself may predispose to PML. The mechanism of this putative predisposition of SLE patients to the development of PML remains unexplained.
Insights
Progressive multifocal leukoencephalopathy (PML) is a rare, fatal infection in immunocompromised patients. Systemic lupus erythematosus (SLE) patients may have an unexplained predisposition to PML, even with minimal immunosuppression.
Area of Science:
- Neurology
- Rheumatology
- Infectious Diseases
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, fatal opportunistic infection.
- PML is a known complication in immunocompromised patients, including those with rheumatic diseases on immunosuppressive therapy.
- Recent cases of PML associated with natalizumab and rituximab highlight the risk in rheumatic disease patients.
Purpose of the Study:
- To review the occurrence of PML in patients with rheumatic diseases.
- To investigate the association between systemic lupus erythematosus (SLE) and PML.
- To explore potential predisposing factors for PML in SLE patients.
Main Methods:
- Literature review of reported PML cases in patients with rheumatic diseases.
- Analysis of PML incidence in SLE patients, considering levels of immunosuppression.
Main Results:
- Nearly two-thirds of reported PML cases in rheumatic diseases occurred in SLE patients.
- Over 40% of PML cases in SLE patients involved minimal iatrogenic immunosuppression.
- This suggests SLE itself may predispose patients to PML.
Conclusions:
- SLE patients appear to have a higher predisposition to PML than other rheumatic disease patients.
- The underlying mechanism for SLE predisposition to PML remains unclear.
- Further research is needed to understand the link between SLE and PML development.
Related Concept Videos
Multiple Sclerosis l: Introduction
Encephalitis l: Introduction
Rocky Mountain Spotted Fever
Rheumatic Heart Disease I: Introduction
Encephalitis ll: Pathophysiology
Cryptococcal Meningitis